Document mp0j0RjKewvY6ZBqa90kEqN3d

ou Ae226- 191 D 3M MEDICAL DEPARTMENT, CORPORATE TOXICOLOGY Title: Comparative Molecular Biology of Perfluorooctanesulfonate (PFOS, T6295), N-ethyl perfluorooctanesulfonamido ethanol (N-EtFOSE, T-6316), N-Ethyl perfluorooctanesulfonamide (N-EtFOSA, T-6868),Perfluorooctanesulfonamido acetate (FOSAA, T-7071), and/or Perfluorooctanesulfonamide (FOSA, Rats and Guinea Pigs following Oral dosing. T-7132) of in. ees dus, 162008 AMENDED Final Report Study Numbers. T6255, T-6316.4, T-69682, T0711, T7132.1 `Strategic Toxicology Study Number: DT-15-B Sponsor: StudyLocation 3M Specialty Chemicals Division 3M Center, Building 236 Saint Paul MN 55133-3220 1. 3M Stiegic Alemativ Toxceogy Laboratory 3M Center, Building 270-SB-181 Saint Paul, MN 55133-3220 2. University of Minnesota, Duluth Dept.ofBiochemistry and Molecular Biology Schoolof Medicine : StudyDirector: Study Toxicologist: Duluth, MN 55812-2496 Hovicnon Spec Andrew M. Seacat Ph.D., DABT 3M Medical Dept. Corporate Toxicology and Regulatory Services Deanna Luebker M.S Senior Toxicologist 3M Medical Dept. In-Life Start Date In-Life End Date In-Life Start Date eiee onrison In-Life Start Date Protocol: Protocol: Amendment #1: AAmmeennddmmeenntts:. Amendment #2: 11/16/1998 11/20/1998 03/01/1999 0023230250001 02/19/2001 CnoRoR SDRTPTITS.6B29538, T-63164, 68682, T0711, T7132. "LTihneXpuurapnosdeDfroargthAinsdaemresnwdrmoetnetinwaAsppteoncdhiaxngGeEt(hpeacgoen5c9l)uswihoincdhrraewand:in the summary that TPhFeOSor,igw"ihTnehatlehsseetradtPaetFmaOesnSth:owwaesdadthmaitniFsOteSrAeddwiarsecctolnsyiosrtefnotrlymeiddeanstiafied amset2ambeotlaibtoel,ibtuetotfhe Sourceof the amino group is not readily apparent." Was chaTnhgeesdetodarteaads:howed that FOSA was consistently identified as a metabolite of PFOS, but that the sourceofthe amino group is not readily apparent." "SbTuehpcepaoruarstteieoadnlalbolfyfttohhreethdaeadstmeaicpnrhieassntegenerteseddwceiornmetphtoihsuatnsdttushd,ey.obreiTsgihidanetaslcPocnFocnOlcSul,suishoianovnewwaaasssunlonftootenndatiimrreiecdltoylycgorroruepct wSiutlhfionnatmhiedpearmeonitectyomcpoonutanidn.inTghceoremfpoorue,ndtshewliokeluybselotuhdrceepoafretnhtecaommipnoougnrdouiptseflofr. There piserqfualnutoirtoaotcitvaeneesvuildfeonncaemiindetshewseersetumdeiteasbosluigzgeedstfiirnsgt that the to POS. followed by metabolism of t1h0atFOPSFOAScbaamcek tforoamsuthlefoPnFamOiSded.oTsehegroonulpys,evniodtetnhceepfeorrfalpuoosrsoiobclteanmcestualbfoonlaimsimdoofPROS dSetruidviaestiavneaplayrzeendtactoRmopcoheusntderd,ostheegcroonutprso.l Fgurrotuhperlmivoerres,aimnptlweso houatdoafhtihgrheebaicnkdegpreonudnedntof FcoOnSvAer,ssiuognogefstPiFngOSpostosiPblFeOcSoAntwaomiunladtihoanveofttohbeelvievreirfsiaemdpbleys.furTthheerresftourdei,esas stated, the Dr Anders is in agreement with the amended conclusion stated above. 2703 238 335 335 33% ga T2 PiEoHpRoB: d Rz i1h)E HT EEEERE] i ary gad ned hE HL | ed wd ed ed 1H] (7 shh ni met HE i i : alfaofl aal oa tHHL S ggg al hh E LE0% wr Strate: Final Report Amendment #1 prepared by, L ---- at0]iBonwls Andrew M. Seacat, PhD, DABT fufer Date C2205